An autism trial will use brain waves to select participants. Here is what that does—and does not—mean.

What is changing in the CLARITY trial?

CLARITY (ClinicalTrials.gov identifier NCT07439510) began as a study of codabakalner for fragile X syndrome. Spinogenix announced a new Phase 2b study in idiopathic autism—autism without an identified syndrome such as fragile X. The autism researchers plan to enroll participants whose screening electroencephalogram (EEG) shows elevated resting gamma-band power. An EEG records patterns of electrical brain activity through scalp electrodes.

The goal is to test a narrower biological hypothesis: might a medicine targeting BK potassium channels help some people with elevated gamma activity? The trial must determine whether the drug improves outcomes that matter and whether the benefits outweigh harms. Selecting participants with a biomarker cannot answer those questions in advance.

Where did the “one in five” statistic come from?

An October 8 medRxiv preprint compared EEG recordings from 159 people with non-syndromic autism and 41 males with full-mutation fragile X syndrome. Using a threshold derived from the fragile X sample, 35 of 159 autistic participants (22%) met the researchers' elevated-gamma definition. Among the adult subgroup, 23 of 72 (31.9%) met that threshold.

Those percentages describe this study sample, not all autistic people. The analysis was cross-sectional, did not test the new drug in autistic participants, and has not yet been peer reviewed. Spinogenix funded the analysis and several authors are employees or advisers. The researchers did not identify clinical characteristics that reliably separated those with and without this particular EEG signature. Larger independent studies must test whether the finding replicates and whether it identifies people who actually benefit from the intervention.

What do we know about codabakalner so far?

Codabakalner is an investigational oral molecule that increases activity of BK potassium channels, which help regulate neuronal signaling. A published randomized crossover study gave single doses to 10 adult men with fragile X syndrome. It reported changes in EEG measures and exploratory attention/executive-function test results. A small, short-term fragile X study cannot establish longer-term safety or effectiveness, and it does not demonstrate benefit in idiopathic autism.

The new Phase 2b autism arm will need to evaluate outcomes, side effects, durability and whether the EEG criterion meaningfully predicts who benefits. Neither an EEG change nor a company's announcement alone shows improvements in everyday quality of life.

What is established care now?

Care should still begin with the autistic person's own priorities: communication access, sensory accommodations, school or work participation, sleep, independence and co-occurring concerns when present. According to the CDC, tailored developmental, educational, behavioral and psychological supports can help with individualized goals; medication may be used for specific co-occurring symptoms, but there is no medication proven to treat autism's core characteristics. An investigational drug does not replace support that is useful today.

Questions worth keeping for future trial updates

1. Will the study show benefit on pre-specified, person-centered outcomes—not only EEG measures?
2. How does the study validate the gamma threshold across ages and different EEG equipment?
3. Who can participate in the autism arm, and what exclusions or adverse effects are reported?
4. Will results be independently replicated and peer reviewed before clinical claims are made?
5. Does the treatment improve something participants themselves identify as important?

For families: You do not need to obtain an EEG or change any treatment because of this announcement. If research participation is of interest, review the official trial record with a clinician when enrollment details are available.